A 4.6 kg infant with Wiskott-Aldrich syndrome received an accidental overdose of busulfan during preparation for allogeneic stem cell transplantation. Pharmacokinetic analysis of plasma busulfan levels alerted staff to the dosing error. Hemodialysis was immediately performed and resulted in accelerated clearance of busulfan. There were no acute neurologic and hepatic side-effects of the busulfan overdose, and despite 2 months of cough accompanied by rales, the patient is now free of pulmonary symptoms. Stable partial donor chimerism occurred after transplantation. At present, the patient is thriving and infection-free 12 months after transplantation, although his platelet count remains at the lower limit of normal. Bone Marrow Transplantation (2001) 27, 551-553. Keywords: busulfan; hemodialysis; overdose; WiskottAldrich syndrome Busulfan is a potent immunosuppressant and antileukemia agent that has been used in the context of allogeneic stem cell transplantation for nearly 20 years. It has a very narrow therapeutic index; acute toxicity may be related to absorption and disposition of the drug and its metabolites. The absorption of busulfan is highly variable, particularly in infants and small children. Measurement of plasma busulfan levels is used to monitor its disposition, to ensure therapeutic drug levels, and may prevent excess drug toxicity, particularly to the hepatic vasculature, that is associated with high plasma busulfan levels.
Busulfan is a potent immunosuppressant and antileukemia agent that has been used in the context of allogeneic stem cell transplantation for nearly 20 years. It has a very narrow therapeutic index; acute toxicity may be related to absorption and disposition of the drug and its metabolites. The absorption of busulfan is highly variable, particularly in infants and small children. Measurement of plasma busulfan levels is used to monitor its disposition, to ensure therapeutic drug levels, and may prevent excess drug toxicity, particularly to the hepatic vasculature, that is associated with high plasma busulfan levels. 1 The exact role of pharmacokinetic monitoring on the prevention of busulfan-related toxicities in children is uncertain. 2, 3 We describe a case of inadvertent busulfan overdose in an infant, that occurred during preparation for allogeneic bone marrow transplantation, and the subsequent removal of busulfan by hemodialysis. Our results suggest that hemodialysis can be used to enhance clearance of busulfan.
Case report
A 4.6 kg male infant with Wiskott-Aldrich syndrome (WAS) was referred for bone marrow transplant (BMT) from his HLA-identical sister. Diagnosis was suggested by the family history and confirmed by the presence of thrombocytopenia and mutation of the WASP protein. The planned preparative regimen for BMT was busulfan 4 mg/kg p.o. as crushed pills in divided doses daily for 4 days (total dose,16 mg/kg), followed by cyclophosphamide 50 mg/kg daily for 4 days. Phenytoin anti-convulsant prophylaxis was administered. Plasma busulfan levels were drawn at 0, 15, 30, 60, 90, 120, 180, 240, 300 and 360 min after the first dose of the drug. Additional busulfan levels were obtained as indicated later in the text. The pharmacokinetic analysis that followed busulfan dose No. 1, revealed a dosing error. The patient had already received three doses of 4 mg/kg busulfan at intervals of 6 h instead of the planned dose of 1 mg/kg. Because of the patient's age, and because nearly 4 h had passed since the last busulfan dose, nasogastric lavage was not performed and activated charcoal was not administered.
The patient was heavily sedated and No. 4 and No. 3 French single-lumen catheters were inserted in his femoral vein and artery, respectively.
Hemodialysis was performed using a Fresenius 3 dialyzer with a surface area of 0.4 m 2 (Fresenius, Bad Hamburg, Germany). Volumes of the dialyzer and dialysis tubing were 28 ml each. The dialysis set was primed with plasma. Dialysis began 8.25 h after the last dose of busulfan, and lasted 180 min at an average blood flow rate of 68.3 ml/min. Heparin was administered to maintain an activated whole blood clotting time of 160 to 200 s.
Busulfan concentrations in plasma and dialysate were measured by gas chromatography using an electron capture detector (Hewlett Packard model 5790A, Hewlett Packard Corporation, Wilmington, DE, USA). The method is based on derivatization with sodium iodide; 1,5 pentanediol dimethylsulfonate was used as the interval standard. Data were collected with the Borwin Integration system (Borwin Jasco, Tokyo, Japan).
The mean coefficients of variation in our laboratory for 1 m and 3 m busulfan concentrations were 7% and 3.6%, respectively. The lower limit of detection is 0.2 m and the targeted area under the concentration-time curve (AUC) is 1100 m × min.
Pharmacokinetic analyses of busulfan plasma and dialysate concentrations were performed using a non-compartmental analysis model for extravascular absorption (Kinetica 1.0, Innaphase, Clinical Information Engineering France, Champs sur Marne, France). This method uses model-independent equations, on the assumption that the terminal elimination process can be approximated by an exponential equation. This is equivalent to assuming that a straight line can approximate the logarithmic transformation of the data belonging to the terminal elimination phase of the drug.
Results of busulfan pharmacokinetic studies are shown in Table 1 .
AUC for the initial dose of busulfan was 2277 m × min, with a predicted half-life of 7.46 h. Peak plasma concentration was achieved at 4 h after the first dose. Busulfan levels in plasma at 150 min after the third dose, and immediately prior to initiation of dialysis were 10.94 and 3.82 m, respectively. This indicates a plasma half-life of 1.64 h, an AUC of 1559 m × min during the 2.5 h prior to dialysis and a clearance of 40.8 ml/min/kg. Three h of hemodialysis reduced the busulfan plasma concentration from 3.82 to 1.08 m, corresponding to a clearance of 60.8 ml/min. This is an increase in busulfan clearance from 40.8 to 60.8 ml/min/kg due to dialysis. Busulfan concentration in the dialysate was 82.8 m.
After hemodialysis, the patient was returned to the transplant unit. The pretransplant conditioning regimen was modified: cyclophosphamide 120 mg/kg instead of the planned 200 mg/kg, and antithymocyte globulin were added. No additional busulfan was administered. Graft-versus-host disease (GVHD) prophylaxis consisted of short course methotrexate and cyclosporin A.
Complications that occurred during the first 30 days after transplantation included WHO grade 3 mucositis, a single episode of lower gastrointestinal tract bleeding, and two episodes of venous catheter-related bacteremia. Mild veno- occlusive disease of the liver occurred (maximum bilirubin 2.1 mg/dl and maximal weight gain 4.4%). Acute neurotoxicity was not noted. The patient's absolute neutrophil count reached 1000/l on day +25. Mild biopsy-proven GVHD of the stomach manifesting as feeding intolerance, occurred on day +60 and responded to prednisone. Cough and rales on auscultation were found during the 3rd and 4th month after transplant but subsequently resolved. Chimerism studies (fluorescent in situ hybridization) revealed full donor chimerism on day +50, but subsequent measurements over the ensuing months showed a decrease to a stable level of approximately 30% donor cells. At present, the patient is free of infections, with a platelet count of approximately 85 × 10 9 /l.
Discussion
This patient received the equivalent of three daily doses of busulfan within 12 h. The dosing error became apparent when pharmacokinetic studies obtained after dose No. 1 indicated an inordinately high AUC. Although relatively few data points were measured, it is clear that the clearance of busulfan was augmented by hemodialysis. Although hemodialysis is particularly cumbersome in small infants, it was tolerated without complications in this patient. To the best of our knowledge, this is the first case of accidental busulfan overdose in an infant which was treated by hemodialysis.
Busulfan is a small, water-soluble molecule, that does not significantly bind to plasma proteins, 4 although its volume of distribution is large. There is scant literature-based evidence that busulfan is removed by hemodialysis. In one report, a patient on maintenance hemodialysis with concurrent acute myeloid leukemia was treated with low-dose busulfan on dialysis and no-dialysis days; enhanced drug clearance was documented on the days that he underwent dialysis. 5 Ullery and colleagues 6 demonstrated efficient clearance of busulfan by hemodialysis in a patient with end stage renal disease who underwent stem cell transplantation for treatment of lymphoma. Our data demonstrate that hemodialysis can be used to enhance busulfan clearance after accidental drug overdose.
Shaw et al 7 administered busulfan in single daily doses of 4 mg/kg instead of the traditional dosing of 1 mg/kg four times a day described by Santos et al, 8 without an increase in daily drug exposure (as measured by AUC), and without an increase in drug toxicity. Our patient received three times the dose recommended by Shaw et al within a period of 12 h. Indeed, we were surprised by the lack of acute busulfan toxicity in this child despite the initially intense drug exposure. Specifically, there were no seizures, severe hepatic veno-occlusive disease, nor chronic lung disease. Unfortunately, however, attenuation of the planned pre-transplant conditioning regimen may have compromised graft function. We are reluctant to add donor lymphocytes at this time because our patient has normal T cell function and is free of infections. The lack of other stigmata of WAS at this time suggests that the current level of partial donor chimerism is sufficient for the treatment of the patient's disease.
Cytotoxic drug dosing errors during stem cell transplantation conditioning have been reported. 9 They can be prevented by strict adherence to pre-written protocols, checking of physician orders by the nursing and pharmacy staff, and cross-checking of the drug dose at the patient's bedside prior to administration. Experienced and alert staff members will often notice such dosing errors before the medication is administered to the patient. 10 Dosing errors of cytotoxic medications in the stem cell transplantation setting must be avoided. In cases of busulfan overdose, hemodialysis can be used to enhance drug clearance and avoid excessive toxicity.
